Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1028

1.

Pulmonary hypertension is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation for myelofibrosis.

Gupta R, Jamal F, Yang D, Chendri C, Aldoss I, Malki MA, Mei M, Salhotra A, Dobrin S, Tran M, Venkataraman K, Palmer J, Stein AS, Sandhu K, Khaled S, Aribi A, Marcucci G, Forman SJ, Snyder D, Nakamura R, Ali H, Pullarkat V.

Bone Marrow Transplant. 2019 Nov 6. doi: 10.1038/s41409-019-0741-8. [Epub ahead of print]

PMID:
31695170
2.

Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

Gökbuget N, Kantarjian HM, Brüggemann M, Stein AS, Bargou RC, Dombret H, Fielding AK, Heffner L, Rigal-Huguet F, Litzow M, O'Brien S, Zugmaier G, Gao S, Nagorsen D, Forman SJ, Topp MS.

Blood Adv. 2019 Oct 22;3(20):3033-3037. doi: 10.1182/bloodadvances.2019000457.

3.

Massively-Parallelized, Deterministic Mechanoporation for Intracellular Delivery.

Dixit HG, Starr R, Dundon ML, Pairs PI, Yang X, Zhang Y, Nampe D, Ballas CB, Tsutsui H, Forman SJ, Brown CE, Rao MP.

Nano Lett. 2019 Oct 28. doi: 10.1021/acs.nanolett.9b03175. [Epub ahead of print]

PMID:
31647675
4.

Influence of donor KIR genotypes on reduced relapse risk in acute myelogenous leukemia after hematopoietic stem cell transplantation in patients with CMV reactivation.

Nakamura R, Gendzekhadze K, Palmer J, Tsai NC, Mokhtari S, Forman SJ, Zaia JA, Senitzer D, Marcucci G, Stein A.

Leuk Res. 2019 Sep 28;87:106230. doi: 10.1016/j.leukres.2019.106230. [Epub ahead of print]

PMID:
31644966
5.

Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies.

Siddiqi T, Frankel P, Beumer JH, Kiesel BF, Christner S, Ruel C, Song JY, Chen R, Kelly KR, Ailawadhi S, Kaesberg P, Popplewell L, Puverel S, Piekarz R, Forman SJ, Newman EM.

Leuk Lymphoma. 2019 Oct 16:1-9. doi: 10.1080/10428194.2019.1672052. [Epub ahead of print]

PMID:
31617432
6.

Efficacy of low-dose zoster prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation.

Mascarenhas K, Teh JB, Peng K, Kim H, Sy A, Forman SJ, Wong FL, Nakamura R, Dadwal SS, Armenian SH.

Bone Marrow Transplant. 2019 Oct 15. doi: 10.1038/s41409-019-0717-8. [Epub ahead of print] No abstract available.

PMID:
31616064
7.

Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical Trial.

Gooderham MJ, Forman SB, Bissonnette R, Beebe JS, Zhang W, Banfield C, Zhu L, Papacharalambous J, Vincent MS, Peeva E.

JAMA Dermatol. 2019 Oct 2. doi: 10.1001/jamadermatol.2019.2855. [Epub ahead of print]

8.

Personal Phone Calls Lead to Decreased Rates of Missed Appointments in an Adolescent/Young Adult Practice.

Penzias R, Sanabia V, Shreeve KM, Bhaumik U, Lenz C, Woods ER, Forman SF.

Pediatr Qual Saf. 2019 Jul 29;4(4):e192. doi: 10.1097/pq9.0000000000000192. eCollection 2019 Jul-Aug.

9.

Drug-selective Anesthetic Insensitivity of Zebrafish Lacking γ-Aminobutyric Acid Type A Receptor β3 Subunits.

Yang X, Jounaidi Y, Mukherjee K, Fantasia RJ, Liao EC, Yu B, Forman SA.

Anesthesiology. 2019 Dec;131(6):1276-1291. doi: 10.1097/ALN.0000000000002963.

PMID:
31567362
10.

CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies.

Qin H, Dong Z, Wang X, Cheng WA, Wen F, Xue W, Sun H, Walter M, Wei G, Smith DL, Sun X, Fei F, Xie J, Panagopoulou TI, Chen CW, Song JY, Aldoss I, Kayembe C, Sarno L, Müschen M, Inghirami GG, Forman SJ, Kwak LW.

Sci Transl Med. 2019 Sep 25;11(511). pii: eaaw9414. doi: 10.1126/scitranslmed.aaw9414.

PMID:
31554741
11.

Protective effect of HLA-DPB1 mismatch remains valid in reduced-intensity conditioning unrelated donor hematopoietic cell transplantation.

Malki MMA, Gendzekhadze K, Stiller T, Mokhtari S, Karanes C, Parker P, Snyder D, Forman SJ, Nakamura R, Nademanee A.

Bone Marrow Transplant. 2019 Sep 24. doi: 10.1038/s41409-019-0694-y. [Epub ahead of print]

PMID:
31551519
12.

Long-Term Outcomes of Patients with Acute Myelogenous Leukemia Treated with Myeloablative Fractionated Total Body Irradiation TBI-Based Conditioning with a Tacrolimus- and Sirolimus-Based Graft-versus-Host Disease Prophylaxis Regimen: 6-Year Follow-Up from a Single Center.

Salhotra A, Hui S, Yang D, Mokhtari S, Mei M, Al Malki MM, Aldoss I, Ali H, Sandhu KS, Aribi A, Khaled S, Dandapani S, Peng K, Teh JB, Murata-Collins J, Budde E, Dadwal S, Pullarkat V, Snyder D, Spielberger R, Wong J, Armenian S, Marcucci G, Forman SJ, Nakamura R, Stein A.

Biol Blood Marrow Transplant. 2019 Sep 16. pii: S1083-8791(19)30628-7. doi: 10.1016/j.bbmt.2019.09.017. [Epub ahead of print]

PMID:
31536825
13.

Effect of a Multicomponent Home-Based Physical Therapy Intervention on Ambulation After Hip Fracture in Older Adults: The CAP Randomized Clinical Trial.

Magaziner J, Mangione KK, Orwig D, Baumgarten M, Magder L, Terrin M, Fortinsky RH, Gruber-Baldini AL, Beamer BA, Tosteson ANA, Kenny AM, Shardell M, Binder EF, Koval K, Resnick B, Miller R, Forman S, McBride R, Craik RL.

JAMA. 2019 Sep 10;322(10):946-956. doi: 10.1001/jama.2019.12964.

PMID:
31503309
14.

Knowing our patients: the value of recognising occupational illness.

Williams N, Forman S.

BMJ. 2019 Sep 9;366:l5385. doi: 10.1136/bmj.l5385. No abstract available.

PMID:
31501088
15.

Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for Cancer.

Zhu Y, Smith DJ, Zhou Y, Li YR, Yu J, Lee D, Wang YC, Di Biase S, Wang X, Hardoy C, Ku J, Tsao T, Lin LJ, Pham AT, Moon H, McLaughlin J, Cheng D, Hollis RP, Campo-Fernandez B, Urbinati F, Wei L, Pang L, Rezek V, Berent-Maoz B, Macabali MH, Gjertson D, Wang X, Galic Z, Kitchen SG, An DS, Hu-Lieskovan S, Kaplan-Lefko PJ, De Oliveira SN, Seet CS, Larson SM, Forman SJ, Heath JR, Zack JA, Crooks GM, Radu CG, Ribas A, Kohn DB, Witte ON, Yang L.

Cell Stem Cell. 2019 Oct 3;25(4):542-557.e9. doi: 10.1016/j.stem.2019.08.004. Epub 2019 Sep 5.

PMID:
31495780
16.

Risk of venous thromboembolism in patients with non-Hodgkin lymphoma surviving blood or marrow transplantation.

Gangaraju R, Chen Y, Hageman L, Wu J, Francisco L, Kung M, Ness E, Parman M, Weisdorf DJ, Forman SJ, Arora M, Armenian SH, Bhatia S.

Cancer. 2019 Aug 30. doi: 10.1002/cncr.32488. [Epub ahead of print]

PMID:
31469420
17.

Long-term outcome of allogeneic hematopoietic stem cell transplantation from unrelated donor using tacrolimus/sirolimus-based GVHD prophylaxis: impact of HLA mismatch.

Al Malki MM, Gendzekhadze K, Yang D, Mokhtari S, Parker P, Karanes C, Palmer J, Snyder D, Forman SJ, Nademanee A, Nakamura R.

Transplantation. 2019 Aug 19. doi: 10.1097/TP.0000000000002932. [Epub ahead of print]

PMID:
31449184
18.

Association between Clonal Hematopoiesis and Late Nonrelapse Mortality after Autologous Hematopoietic Cell Transplantation.

Slavin TP, Teh JB, Weitzel JN, Peng K, Wong FL, Qin H, Wang J, Wu X, Mei M, Pillai R, Wang Y, Tsang KK, Pozhitkov A, Krishnan A, Forman SJ, Armenian SH.

Biol Blood Marrow Transplant. 2019 Aug 22. pii: S1083-8791(19)30527-0. doi: 10.1016/j.bbmt.2019.08.013. [Epub ahead of print]

19.

Venetoclax and hypomethylating agents in TP53-mutated acute myeloid leukaemia.

Aldoss I, Zhang J, Pillai R, Shouse G, Sanchez JF, Mei M, Nakamura R, Stein AS, Forman SJ, Marcucci G, Pullarkat V.

Br J Haematol. 2019 Oct;187(2):e45-e48. doi: 10.1111/bjh.16166. Epub 2019 Aug 22. No abstract available.

PMID:
31441045
20.

Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study.

Jabbour EJ, Gökbuget N, Kantarjian HM, Thomas X, Larson RA, Yoon SS, Ghobadi A, Topp MS, Tran Q, Franklin JL, Forman SJ, Stein AS.

Cancer. 2019 Dec 1;125(23):4181-4192. doi: 10.1002/cncr.32335. Epub 2019 Aug 21.

PMID:
31433496
21.

Radiation Related Toxicities Using Organ Sparing Total Marrow Irradiation Transplant Conditioning Regimens.

Shinde A, Yang D, Frankel P, Liu A, Han C, Del Vecchio B, Schultheiss T, Cheng J, Li R, Kim D, Radany EH, Hui S, Somlo G, Rosenthal J, Stein A, Forman S, Wong JYC.

Int J Radiat Oncol Biol Phys. 2019 Aug 14. pii: S0360-3016(19)33643-0. doi: 10.1016/j.ijrobp.2019.08.010. [Epub ahead of print]

PMID:
31421151
22.

Late mortality after bone marrow transplant for chronic myelogenous leukemia in the context of prior tyrosine kinase inhibitor exposure: A Blood or Marrow Transplant Survivor Study (BMTSS) report.

Wu J, Chen Y, Hageman L, Francisco L, Ness EC, Parman M, Kung M, Watson JA, Weisdorf DJ, Snyder DS, McGlave PB, Forman SJ, Arora M, Armenian SH, Bhatia R, Bhatia S.

Cancer. 2019 Nov 15;125(22):4033-4042. doi: 10.1002/cncr.32443. Epub 2019 Aug 14.

PMID:
31412155
23.

Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B Cell Lymphoma.

Herrera AF, Chen L, Khajavian S, Chase M, Darrah J, Maloney D, Ho VT, Soiffer RJ, Antin JH, Forman SJ, Nademanee AP, Chen YB, Armand P, Shadman M.

Biol Blood Marrow Transplant. 2019 Aug 5. pii: S1083-8791(19)30513-0. doi: 10.1016/j.bbmt.2019.07.041. [Epub ahead of print]

PMID:
31394277
24.

The feasibility of venetoclax and decitabine in therapy-related acute myeloid leukemia with concurrent advanced non-hematological malignancies.

Otoukesh S, Salhotra A, Marcucci G, Forman SJ, Pullarkat V, Aldoss I.

Leuk Res. 2019 Sep;84:106196. doi: 10.1016/j.leukres.2019.106196. Epub 2019 Jul 30. No abstract available.

PMID:
31377457
25.

Dupilumab shows long-term safety and efficacy in moderate-to-severe atopic dermatitis patients enrolled in a phase 3 open-label extension study.

Deleuran M, Thaçi D, Beck LA, de Bruin-Weller M, Blauvelt A, Forman S, Bissonnette R, Reich K, Soong W, Hussain I, Foley P, Hide M, Bouaziz JD, Gelfand JM, Sher L, Schuttelaar MLA, Wang C, Chen Z, Akinlade B, Gadkari A, Eckert L, Davis JD, Rajadhyaksha M, Staudinger H, Graham NMH, Pirozzi G, Ardeleanu M.

J Am Acad Dermatol. 2019 Jul 30. pii: S0190-9622(19)32465-X. doi: 10.1016/j.jaad.2019.07.074. [Epub ahead of print]

26.

Editorial: Media magic or mayhem?

Pitts S, Forman SF.

Curr Opin Pediatr. 2019 Aug;31(4):433-434. doi: 10.1097/MOP.0000000000000789. No abstract available.

PMID:
31295194
27.

Allogeneic Hematopoietic Cell Transplant for HIV Patients with Hematologic Malignancies: The BMT CTN-0903/AMC-080 Trial.

Ambinder RF, Wu J, Logan B, Durand CM, Shields R, Popat UR, Little RF, McMahon DK, Cyktor J, Mellors JW, Ayala E, Kaplan LD, Noy A, Jones RJ, Howard A, Forman SJ, Porter D, Arce-Lara C, Shaughnessy P, Sproat L, Hashmi SK, Mendizabal AM, Horowitz MM, Navarro WH, Alvarnas JC.

Biol Blood Marrow Transplant. 2019 Nov;25(11):2160-2166. doi: 10.1016/j.bbmt.2019.06.033. Epub 2019 Jul 4.

PMID:
31279752
28.

Venous Thromboembolism in Autologous Blood or Marrow Transplantation Survivors: A Report from the Blood or Marrow Transplant Survivor Study.

Gangaraju R, Chen Y, Hageman L, Wu J, Francisco L, Battles K, Kung M, Ness E, Parman M, Weisdorf DJ, Forman SJ, Arora M, Armenian SH, Bhatia S.

Biol Blood Marrow Transplant. 2019 Nov;25(11):2261-2266. doi: 10.1016/j.bbmt.2019.06.032. Epub 2019 Jul 3.

PMID:
31278995
29.

Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.

Aldoss I, Yang D, Pillai R, Sanchez JF, Mei M, Aribi A, Ali H, Sandhu K, Al Malki MM, Salhotra A, Khaled S, Sun W, O'Donnell M, Snyder D, Nakamura R, Stein AS, Forman SJ, Marcucci G, Pullarkat V.

Am J Hematol. 2019 Oct;94(10):E253-E255. doi: 10.1002/ajh.25567. Epub 2019 Jul 10. No abstract available.

PMID:
31259427
30.

Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report.

Kim HT, Ahn KW, Hu ZH, Davids MS, Volpe VO, Antin JH, Sorror ML, Shadman M, Press O, Pidala J, Hogan W, Negrin R, Devine S, Uberti J, Agura E, Nash R, Mehta J, McGuirk J, Forman S, Langston A, Giralt SA, Perales MA, Battiwalla M, Hale GA, Gale RP, Marks DI, Hamadani M, Ganguly S, Bacher U, Lazarus H, Reshef R, Hildebrandt GC, Inamoto Y, Cahn JY, Solh M, Kharfan-Dabaja MA, Ghosh N, Saad A, Aljurf M, Schouten HC, Hill BT, Pawarode A, Kindwall-Keller T, Saba N, Copelan EA, Nathan S, Beitinjaneh A, Savani BN, Cerny J, Grunwald MR, Yared J, Wirk BM, Nishihori T, Chhabra S, Olsson RF, Bashey A, Gergis U, Popat U, Sobecks R, Alyea E, Saber W, Brown JR.

Clin Cancer Res. 2019 Aug 15;25(16):5143-5155. doi: 10.1158/1078-0432.CCR-18-3988. Epub 2019 Jun 28.

PMID:
31253630
31.

Media magic or mayhem?

Pitts S, Forman S.

Curr Opin Pediatr. 2019 Jun 10. doi: 10.1097/MOP.0000000000000789. [Epub ahead of print] No abstract available.

PMID:
31188169
32.

Allogeneic Hematopoietic Cell Transplantation Outcomes in Patients Carrying Isocitrate Dehydrogenase Mutations.

Salhotra A, Afkhami M, Yang D, Mokhtari S, Telatar M, Gu D, Pillai RK, Weisenburger DD, Murata-Collins J, Weigel D, Aoun P, Aldoss I, Al Malki MM, Khaled S, Mei M, Ali H, Aribi A, Budde E, Sandhu K, O'Donnell M, Snyder D, Pullarkat V, Forman SJ, Marcucci G, Nakamura R, Stein A.

Clin Lymphoma Myeloma Leuk. 2019 Jul;19(7):e400-e405. doi: 10.1016/j.clml.2019.04.007. Epub 2019 Apr 26.

PMID:
31155409
33.

CD123 CAR T cells for the treatment of myelodysplastic syndrome.

Stevens BM, Zhang W, Pollyea DA, Winters A, Gutman J, Smith C, Budde E, Forman SJ, Jordan CT, Purev E.

Exp Hematol. 2019 Jun;74:52-63.e3. doi: 10.1016/j.exphem.2019.05.002. Epub 2019 May 25.

34.

Favorable outcomes for allogeneic hematopoietic cell transplantation in elderly patients with NPM1-mutated and FLT3-ITD-negative acute myeloid leukemia.

Aldoss I, Nakamura R, Yang D, Salhotra A, Stein AS, Pullarkat V, Forman SJ, Marcucci G.

Bone Marrow Transplant. 2019 May 14. doi: 10.1038/s41409-019-0553-x. [Epub ahead of print] No abstract available.

PMID:
31089274
35.

Impact of Sarcopenia on Adverse Outcomes After Allogeneic Hematopoietic Cell Transplantation.

Armenian SH, Xiao M, Berano Teh J, Lee B, Chang HA, Mascarenhas K, Lee S, Iukuridze A, Xie JJ, Scott JM, Jones LW, Lennie Wong F, Forman SJ, Nakamura R.

J Natl Cancer Inst. 2019 Feb 14. pii: djy231. doi: 10.1093/jnci/djy231. [Epub ahead of print]

PMID:
30951603
36.

The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study.

Bissonnette R, Maari C, Forman S, Bhatia N, Lee M, Fowler J, Tyring S, Pariser D, Sofen H, Dhawan S, Zook M, Zammit DJ, Usansky H, Denis L, Rao N, Song T, Pavel AB, Guttman-Yassky E.

Br J Dermatol. 2019 Oct;181(4):733-742. doi: 10.1111/bjd.17932. Epub 2019 May 6.

37.

Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials.

Jemec GBE, Okun MM, Forman SB, Gulliver WPF, Prens EP, Mrowietz U, Armstrong AW, Geng Z, Gu Y, Williams DA, Teixeira HD, Kimball AB.

Br J Dermatol. 2019 Nov;181(5):967-975. doi: 10.1111/bjd.17919. Epub 2019 Aug 14.

PMID:
30916379
38.

Understanding Caregiver Quality of Life in Caregivers of Hospitalized Older Adults With Cancer.

Hsu T, Nathwani N, Loscalzo M, Chung V, Chao J, Karanes C, Koczywas M, Forman S, Lim D, Siddiqi T, Stein A, Twardowski P, Nademanee A, Pal S, Siccion E, Hein M, Akiba C, Goldstein L, Smith D, Ma H, Feng T, Hurria A.

J Am Geriatr Soc. 2019 May;67(5):978-986. doi: 10.1111/jgs.15841. Epub 2019 Mar 22.

PMID:
30901083
39.

"I's" on the prize: A systematic review of individual differences in Contingency Management treatment response.

Forster SE, DePhilippis D, Forman SD.

J Subst Abuse Treat. 2019 May;100:64-83. doi: 10.1016/j.jsat.2019.03.001. Epub 2019 Mar 7.

PMID:
30898330
40.

Effects of Anticholinesterase Reversal Under General Anesthesia on Postoperative Cardiovascular Complications: A Retrospective Cohort Study.

Shaydenfish D, Scheffenbichler FT, Kelly BJ, Lihn AL, Deng H, Nourmahnad A, Xu X, Houle TT, Eikermann M, Forman SA.

Anesth Analg. 2019 Mar 14. doi: 10.1213/ANE.0000000000004099. [Epub ahead of print]

PMID:
30896593
41.

IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype.

Alizadeh D, Wong RA, Yang X, Wang D, Pecoraro JR, Kuo CF, Aguilar B, Qi Y, Ann DK, Starr R, Urak R, Wang X, Forman SJ, Brown CE.

Cancer Immunol Res. 2019 May;7(5):759-772. doi: 10.1158/2326-6066.CIR-18-0466. Epub 2019 Mar 19.

PMID:
30890531
42.

Late mortality in blood or marrow transplant survivors with venous thromboembolism: report from the Blood or Marrow Transplant Survivor Study.

Gangaraju R, Chen Y, Hageman L, Wu J, Francisco L, Kung M, Ness E, Parman M, Weisdorf DJ, Forman SJ, Arora M, Armenian SH, Bhatia S.

Br J Haematol. 2019 Jul;186(2):367-370. doi: 10.1111/bjh.15866. Epub 2019 Mar 18. No abstract available.

PMID:
30883690
43.

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function.

Wang D, Starr R, Alizadeh D, Yang X, Forman SJ, Brown CE.

J Vis Exp. 2019 Feb 27;(144). doi: 10.3791/59275.

44.

Acute Lymphoblastic Leukemia in the Older Adult.

Aldoss I, Forman SJ, Pullarkat V.

J Oncol Pract. 2019 Feb;15(2):67-75. doi: 10.1200/JOP.18.00271.

PMID:
30763199
45.

Post-Allogeneic Hematopoietic Stem Cell Transplantation Eculizumab as Prophylaxis Against Hemolysis and Thrombosis for Patients with Hematologic Disorders Associated with Paroxysmal Nocturnal Hemoglobinuria Clones.

Mei M, Gupta R, O'Donnell M, Al Malki MM, Aldoss I, Ali H, Farol L, Snyder D, Forman SJ, Nakamura R, Khaled S.

Biol Blood Marrow Transplant. 2019 May;25(5):e183-e185. doi: 10.1016/j.bbmt.2019.01.025. Epub 2019 Jan 29.

PMID:
30708188
46.

Monod-Wyman-Changeux Allosteric Shift Analysis in Mutant α1β3γ2L GABAA Receptors Indicates Selectivity and Crosstalk among Intersubunit Transmembrane Anesthetic Sites.

Szabo A, Nourmahnad A, Halpin E, Forman SA.

Mol Pharmacol. 2019 Apr;95(4):408-417. doi: 10.1124/mol.118.115048. Epub 2019 Jan 29.

PMID:
30696720
47.

Exclusive dependence of IL-10Rα signalling on intestinal microbiota homeostasis and control of whipworm infection.

Duque-Correa MA, Karp NA, McCarthy C, Forman S, Goulding D, Sankaranarayanan G, Jenkins TP, Reid AJ, Cambridge EL, Ballesteros Reviriego C; Sanger Mouse Genetics Project; 3i consortium, Müller W, Cantacessi C, Dougan G, Grencis RK, Berriman M.

PLoS Pathog. 2019 Jan 14;15(1):e1007265. doi: 10.1371/journal.ppat.1007265. eCollection 2019 Jan.

48.

Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis.

Al-Mansour Z, Li H, Cook JR, Constine LS, Couban S, Stewart DA, Shea TC, Porcu P, Winter JN, Kahl BS, Smith SM, Marcellus DC, Barton KP, Mills GM, LeBlanc M, Rimsza LM, Forman SJ, Leonard JP, Fisher RI, Friedberg JW, Stiff PJ.

Leuk Lymphoma. 2019 Aug;60(8):1934-1941. doi: 10.1080/10428194.2018.1563691. Epub 2019 Jan 10.

PMID:
30628511
49.

The Bcl-2 inhibitor venetoclax inhibits Nrf2 antioxidant pathway activation induced by hypomethylating agents in AML.

Nguyen LXT, Troadec E, Kalvala A, Kumar B, Hoang DH, Viola D, Zhang B, Nguyen DQ, Aldoss I, Ghoda L, Budde E, Pichiorri F, Rosen S, Forman SJ, Marcucci G, Pullarkat V.

J Cell Physiol. 2019 Aug;234(8):14040-14049. doi: 10.1002/jcp.28091. Epub 2019 Jan 8.

PMID:
30623427
50.

MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen.

Ali H, Aldoss I, Yang D, Mokhtari S, Khaled S, Aribi A, Afkhami M, Al Malki MM, Cao T, Mei M, O'Donnell M, Salhotra A, Pullarkat V, Yang L, Stein AS, Marcucci G, Forman SJ, Nakamura R, Pillai R, Snyder D.

Blood Adv. 2019 Jan 8;3(1):83-95. doi: 10.1182/bloodadvances.2018026658.

Supplemental Content

Loading ...
Support Center